US Pharm. 2009;34(3):36. 

Identifying biosimilars as a major growth driver, Israel-based Teva Pharmaceutical Industries Ltd. has established a joint venture with Switzerland-based Lonza Group Ltd. to develop, manufacture, and market a portfolio of selected biologic pharmaceuticals. The new venture is expected to begin activities during the first quarter of 2009, subject to receipt of any applicable regulatory approvals. Financial details of this agreement are not being disclosed.